$300 Hep C Cure Just as Good as $84,000 Alternative

Non-profit organization DNDi has developed a low-cost hepatitis C treatment that stands to benefit 71 million people.

Protesters / Image: Josep Lago
Protesters / Image: Josep Lago

A recent article from The Guardian had good news for the 71 million people affected by hepatitis C, the blood-borne viral infection that causes 400,000 deaths a year. The non-profit Drugs for Neglected Diseases initiative (DNDi) has teamed up with Egypt’s Pharco Pharmaceuticals to create a two-pill treatment for the disease that’s expected to cost just $300.

The drugs, ravidasvir and sofosbuvir, are a welcome alternative to versions from Gilead and AbbVie, which can cost up to $84,000. The DNDi reported that the new treatment cured 97% of patients within 12 weeks.

Medical Device Innovations Report
Cutting-edge packaging technologies are transforming the medical device sector in PMMI’s “Innovation in Medical Device” report, featuring advanced materials, smart solutions, and evolving regulations. Editors share insights from nearly 300 PACK EXPO booth visits—each product deemed new and truly innovative—alongside video demonstrations of the equipment and materials on display.
Learn More
Medical Device Innovations Report
List: Digitalization Companies From PACK EXPO
Looking for CPG-focused digital transformation solutions? Download our editor-curated list from PACK EXPO featuring top companies offering warehouse management, ERP, digital twin, and MES software with supply chain visibility and analytics capabilities—all tailored specifically for CPG operations.
Download Now
List: Digitalization Companies From PACK EXPO